ReviewAmerican journal of clinical dermatology2026
Emerging Therapeutic Strategies in Cutaneous T-Cell Lymphoma: A Comprehensive Review of Clinical Trials.
Review in American journal of clinical dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCutaneous T-cell lymphomas (CTCL), including mycosis fungoides (MF) and Sézary syndrome (SS), are rare non-Hodgkin lymphomas characterized by skin-homing malignant T cells. While early-stage disease carries favorable prognosis, advanced-stage CTCL has limited treatment options with historically modest response rates and no demonstrated overall survival benefit from systemic therapies.
objectiveTo comprehensively review interventional clinical trials in CTCL registered between January 2015 and December 2025, with emphasis on developments during the last 5 years.
methodsWe conducted a systematic search of ClinicalTrials.gov, supplemented by review of conference proceedings from American Society of Hematology (ASH), American Academy of Dermatology (AAD), and European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Group (EORTC-CLG) meetings (2020-2025). Of 181 studies identified, 134 met inclusion criteria after excluding withdrawn, terminated, duplicate, and supportive care trials.
resultsThe 134 included trials spanned antibody and biologic therapies (n = 31), including payload-delivering agents, immune-engaging antibodies, and bispecific constructs; epigenetic modifiers (n = 20); signaling pathway inhibitors (n = 21); apoptosis modulators and protein degraders (n = 10); immunotherapy (n = 26); cellular therapies (n = 10); and skin-directed modalities (n = 16). Major regulatory milestones included Food and Drug Administration (FDA) approval of denileukin diftitox-cxdl (August 2024) for relapsed/refractory CTCL and breakthrough therapy designation for lacutamab (February 2025) for Sézary syndrome. Lacutamab demonstrated 43% overall response rate with median duration of response of 25.6 months in SS. Chimeric antigen receptor T-cell (CAR-T) therapy overcame the historical barrier of T-cell fratricide, with CTX130 (CD70-directed allogeneic CAR-T) achieving 46% overall response rates (ORR) in patients who were heavily pretreated. Combination strategies pairing histone deacetylase (HDAC) inhibitors with PI3K inhibitors (tenalisib, duvelisib, linperlisib) achieved 50-60% response rates in refractory cases. For early-stage disease, HyBryte (synthetic hypericin) visible light-activated photodynamic therapy demonstrated efficacy in the Phase 3 FLASH trial. The RESMAIN trial, despite meeting its primary PFS endpoint, failed to achieve regulatory approval due to quality-of-life detriments from gastrointestinal toxicity, highlighting the importance of incorporating patient-reported outcomes alongside efficacy measures in this disease setting.
conclusionsThe 2020-2025 period brought meaningful therapeutic advances for CTCL, including new FDA approvals, breakthrough designations, and emergence of cellular therapy. Future development should prioritize patient-reported outcomes as co-primary endpoints, prospective biomarker validation, and combination strategies with non-overlapping toxicity profiles.
Indexed as
Identifiers
41920459What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.